Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 10, 2022, titled "Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Dronedarone Tablets USP, 400 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 10, 2022, titled "Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Dronedarone Tablets USP, 400 mg".